Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities
A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.
Authors
- Francesco Ferrara (ORCID: https://orcid.org/0000-0002-7290-9542)
- Gabriele Bagaglini
- G. Polito (ORCID: https://orcid.org/0009-0004-6158-1045)
- Eduardo Nava (ORCID: https://orcid.org/0000-0003-3259-0511)
- Roberto Langella
- Maurizio Capuozzo (ORCID: https://orcid.org/0000-0001-9488-6057)
- Andrea Zovi (ORCID: https://orcid.org/0000-0002-6528-2171)
- Marcello Vaccaro (ORCID: https://orcid.org/0009-0008-3931-576X)
Institutions
- Università di Camerino (IT)
- Policlinico Umberto I (IT)
- Italian Society of Physiotherapy (IT)
- Regione Lombardia
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1080/14737167.2025.2465445
- Citations
- 1
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.80